Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 381 to 390 of 1090 total matches.
Zafirlukast for Asthma
The Medical Letter on Drugs and Therapeutics • Dec 20, 1996 (Issue 990)
cancer.
DRUG INTERACTIONS — Concurrent administration of zafirlukast with warfarin (Coumadin ...
Zafirlukast (za fir loo kast; Accolate - Zeneca), the first leukotriene receptor anta-gonist approved by the US Food and Drug Administration, is now being heavily promoted for oral maintenance treatment of chronic asthma in patients more than 12 years old. It is not recommended for treatment of acute asthma.
Tramadol/Celecoxib (Seglentis) for Pain
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
hepatitis has occurred with use of celecoxib.
DRUG INTERACTIONS — Tramadol is metabolized
by CYP2D6 to M1 ...
The FDA has approved Seglentis (Esteve/Kowa), an
oral combination of tramadol hydrochloride, a weak
opioid agonist and weak serotonin and norepinephrine
reuptake inhibitor (SNRI), and celecoxib, a COX-2
selective nonsteroidal anti-inflammatory drug
(NSAID), for use in adults with acute pain that is
severe enough to require an opioid and for which
alternative treatment options are inadequate.
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
is not clear.
DRUG INTERACTIONS – Bremelanotide may slow
gastric emptying and alter the rate and extent ...
The FDA has approved bremelanotide (Vyleesi – Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin
(Addyi), which was approved in 2015, was the first.
Topiramate (Topamax) for Prevention of Migraine
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005 (Issue 1201)
angle-closure glaucoma.
8
It is teratogenic in animals.
DRUG INTERACTIONS — Topiramate has few ...
Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent years some antiepileptic drugs such as valproate (Depakote, and others) and topiramate (Topamax) have also been used for this indication. Valproate was approved by the FDA for such use in 1996. Now topiramate has also been approved.
Montelukast (Singulair) for Perennial Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Oct 24, 2005 (Issue 1220)
— Montelukast is generally well
tolerated. Hepatitis has occurred rarely.
DRUG INTERACTIONS — Drugs ...
Montelukast (Singulair - Merck) is an oral cysteinyl leukotriene D4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
Zavegepant (Zavzpret) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
may be needed for renal or hepatic impairment or for drug interactions.
2. Approximate WAC for one dose ...
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant") to
become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8 doi:10.58347/tml.2023.1681c | Show Introduction Hide Introduction
Veregen: A Botanical for Treatment of Genital Warts
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008 (Issue 1280)
of Michigan Medical School
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW ...
The FDA has approved the marketing of sinecatechins (Veregen - Bradley/Medigene), a botanical drug product, for treatment of external genital and perianal warts. Sinecatechins is a water extract of green tea leaves from Camellia sinensis. It is a mixture of catechins and other green tea components.
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
, or postoperative
motility disorders; its use should be avoided in such
patients.
DRUG INTERACTIONS — SZC can ...
The FDA has approved sodium zirconium cyclosilicate
(Lokelma – AstraZeneca), an oral potassium binder that
exchanges hydrogen and sodium for potassium in the
gastrointestinal (GI) lumen, for treatment of non-life-threatening
hyperkalemia in adults. Sodium zirconium
cyclosilicate (SZC) is the third drug to be approved
for this indication; sodium polystyrene sulfonate and
patiromer (Veltassa) were approved earlier.
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
not have vasoconstrictive effects and is not contraindicated
for use in patients with vascular disease.
DRUG INTERACTIONS ...
The FDA has approved an orally disintegrating tablet
(ODT) formulation of rimegepant (Nurtec ODT –
Biohaven), a small-molecule calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant"), for
acute treatment of migraine with or without aura
in adults. Rimegepant is the second oral gepant to
become available in the US; ubrogepant (Ubrelvy),
which is approved for the same indication, was the
first. Four parenteral CGRP antagonists, erenumab
(Aimovig), fremanezumab (Ajovy), galcanezumab
(Emgality), and eptinezumab (Vyepti), are approved
for prevention of...
Conivaptan (Vaprisol) for Hyponatremia
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006 (Issue 1237)
cannot be ruled out).
DRUG INTERACTIONS — Conivaptan is a substrate and inhibitor of CYP3A4 ...
Conivaptan hydrochloride (Vaprisol - Astellas), a vasopressin antagonist, has been approved by the FDA for short-term intravenous (IV) treatment of euvolemic hyponatremia in hospitalized patients. Euvolemic hyponatremia is most often caused by the syndrome of inappropriate ADH secretion (SIADH), or by hypothyroidism or adrenal insufficiency. The drug has not been approved for treatment of hypervolemic hyponatremia, which is associated with congestive heart failure (CHF), cirrhosis and renal disease. It should not be used in hypovolemic hyponatremia, such as occurs when fluid losses are...